| Description |
1 online resource |
| Series |
Sage business cases |
|
Sage business cases
|
| Summary |
Sage Therapeutics is a neuroscience-focused biopharmaceutical company founded in Cambridge, Massachusetts, in 2010. Their primary focus is on introducing innovative therapies and solutions for brain disorders. Zulresso®, Sage's only marketed product as of 2022, received its FDA approval under priority review in March 2019. Zulresso® is indicated for treating postpartum depression (PPD) in adults. This was the first medication indicated solely for this condition. Sage had to consider various commercial challenges in launching this product. This case will introduce students to some of these challenges through the concept of a market access strategy for a pharmaceutical product |
| Notes |
Description based on XML content |
| Subject |
New products -- Case studies
|
|
Business planning -- Case studies
|
|
Business planning.
|
|
New products.
|
| Genre/Form |
Case studies.
|
| Form |
Electronic book
|
| Author |
Sharma, Taijasi, author
|
|
Munshaw, Supriya, author
|
| ISBN |
9781071915882 |
|
1071915886 |
|
